Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans.

BACKGROUND Statins are commonly used cholesterol-lowering agents that are noted to suppress tumor cell growth in several in vitro and animal models. METHODS We studied the association of lung cancer and the use of statins in patients enrolled in the Veterans Affairs (VA) Health Care System. A retrospective case-control study nested in a cohort study was conducted using prospectively collected data from the Veterans Integrated Service Networks 16 VA database from 1998 to 2004. We analyzed data on 483,733 patients from eight states located in south central United States. The primary variables of interest were lung cancer and the use of statins prior to the diagnosis of lung cancer. Multiple logistic regression analysis was done to adjust for covariates including age, sex, body mass index, smoking, diabetes, and race. Statistical software was used for statistical computing. RESULTS Of the 483,733 patients in the study, 163,662 patients (33.8%) were receiving statins and 7,280 patients (1.5%) had a primary diagnosis of lung cancer. Statin use > 6 months was associated with a risk reduction of lung cancer of 55% (adjusted odds ratio, 0.45; 95% confidence interval, 0.42 to 0.48; p < 0.01). Furthermore, the protective effect of statin was seen across different age and racial groups and was irrespective of the presence of diabetes, smoking, or alcohol use. CONCLUSIONS Statins appear to be protective against the development of lung cancer, and further studies need to be done to define the clinical utility of statins as chemo protective agents.

[1]  M. Garzotto,et al.  Statins and prostate cancer risk: a case-control study. , 2005, American journal of epidemiology.

[2]  Ronit Almog,et al.  Statins and the risk of colorectal cancer. , 2005, The New England journal of medicine.

[3]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[4]  A. Horiguchi,et al.  3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor, Fluvastatin, as a Novel Agent for Prophylaxis of Renal Cancer Metastasis , 2004, Clinical Cancer Research.

[5]  S. Gruber,et al.  HMG CoA reductase inhibitors and the risk of colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Henk-Jan Guchelaar,et al.  The risk of cancer in users of statins. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Heckbert,et al.  The association between 3‐hydroxy‐3‐methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women , 2004, Cancer.

[8]  I. Gram,et al.  Fruits and vegetables and lung cancer: Findings from the European prospective investigation into cancer and nutrition , 2004, International journal of cancer.

[9]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[10]  W. Willett,et al.  Fruits, vegetables and lung cancer: A pooled analysis of cohort studies , 2003, International journal of cancer.

[11]  M. Tatsuta,et al.  Inhibition of lysophosphatidic acid-induced RhoA activation and tumor cell invasion by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. , 2003, International journal of oncology.

[12]  P. Kovacs,et al.  HMG CoA reductase inhibitor fluvastatin arrests the development of implanted hepatocarcinoma in rats. , 2003, Anticancer research.

[13]  Kelvin K. W. Chan,et al.  The statins as anticancer agents. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[15]  N. V. D. Donk,et al.  The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells , 2002, Leukemia.

[16]  A. Walker,et al.  Statin use, hyperlipidaemia, and the risk of breast cancer , 2002, British Journal of Cancer.

[17]  Ann G Zauber,et al.  Statin Use and the Risk of Breast and Prostate Cancer , 2002, Epidemiology.

[18]  M. Minden,et al.  HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis , 2002, Leukemia.

[19]  A. Dabrowska,et al.  Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice , 2002, International journal of cancer.

[20]  J. Soria,et al.  Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. , 2001, Carcinogenesis.

[21]  M. Minden,et al.  Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  J. LeLorier,et al.  Do statins cause cancer? A meta-analysis of large randomized clinical trials. , 2001, The American journal of medicine.

[23]  M. Tatsuta,et al.  Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. , 2001, Cancer research.

[24]  Y. Matsuzawa,et al.  Hepatocellular Carcinoma (hcc) Causes Death in Patients with Cirrhosis and Is One of the Most Prevalent Malignant Tumours Effect of Pravastatin on Survival in Patients with Advanced Hepatocellular Carcinoma. a Randomized Controlled Trial , 2022 .

[25]  B. Davis,et al.  Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project , 2001, Circulation.

[26]  W. Willett,et al.  Prospective study of fruit and vegetable consumption and risk of lung cancer among men and women. , 2000, Journal of the National Cancer Institute.

[27]  L. Blais,et al.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. , 2000, Archives of internal medicine.

[28]  F Gutzwiller,et al.  Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. , 2000, The American journal of clinical nutrition.

[29]  D. Albanes,et al.  Serum α-Tocopherol and Subsequent Risk of Lung Cancer Among Male Smokers , 1999 .

[30]  E. Laws,et al.  A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. , 1998, American journal of clinical oncology.

[31]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[32]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[33]  G. Guyatt,et al.  Effect of HMGcoA Reductase Inhibitors on Stroke , 1998, Annals of Internal Medicine.

[34]  C. Hennekens,et al.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.

[35]  C. Furberg,et al.  Reductase inhibitor monotherapy and stroke prevention. , 1997, Archives of internal medicine.

[36]  G. Stoner,et al.  Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. , 1996, Cancer letters.

[37]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[38]  G. Omenn,et al.  Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. , 1996, The New England journal of medicine.

[39]  D. Samid,et al.  Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  S. Hulley,et al.  Carcinogenicity of lipid-lowering drugs. , 1996, JAMA.

[41]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[42]  C. Hennekens.  Antioxidant vitamins and cancer. , 1994, American Journal of Medicine.

[43]  R. Nowak.  Cancer prevention. Beta-carotene: helpful or harmful? , 1994, Science.

[44]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[45]  M. Gail,et al.  Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. , 1993, Journal of the National Cancer Institute.

[46]  S. Yusuf,et al.  Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.

[47]  S. Kritchevsky.  Dietary lipids and the low blood cholesterol-cancer association. , 1992, American journal of epidemiology.

[48]  C. Boone,et al.  Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. , 1990, Cancer research.

[49]  J. Tobert.  Efficacy and long-term adverse effect pattern of lovastatin. , 1988, The American journal of cardiology.